Optinose Reports First Quarter 2022 Financial Results and Operational Updates Company reports first quarter XHANCE net revenue of $14.8 million increased 35% compared to first quarter 2021 Company expects top-line results from the second of two clinical trials evaluating...

Optinose Announces Reporting Date for First Quarter 2022 Financial Results Conference Call and Webcast to be held May 12, 2022, at 8:00 a.m. Eastern Time YARDLEY, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients...

Optinose to Present at the Needham Virtual Healthcare Conference YARDLEY, Pa., April 08, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...

Optinose Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights Company reports fourth quarter and full year 2021 XHANCE net revenue of $22.5 million and $73.7 million Full year 2021 XHANCE prescriptions increased 28% compared to full year 2020 Company expects...

Optinose Reports Positive Top-line Results in ReOpen1, a Landmark Phase 3 Trial for XHANCE in Chronic Sinusitis XHANCE met both co-primary endpoints in the ReOpen1 trial, demonstrating statistically significant benefits on symptoms and CT scans in patients with chronic sinusitis There are no FDA-approved drug...